newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib

SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration